INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML
Publication
, Conference
Cortes, J; DeAngelo, D; Wang, E; Arana-Yi, C; Zweidler-McKay, P; Munteanu, M; Andreu-Vieyra, C; Erba, H; Blum, W; Traer, E
Published in: HAEMATOLOGICA
June 26, 2017
Duke Scholars
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 26, 2017
Volume
102
Start / End Page
217 / 218
Location
Madrid, SPAIN
Publisher
FERRATA STORTI FOUNDATION
Conference Name
22nd Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Cortes, J., DeAngelo, D., Wang, E., Arana-Yi, C., Zweidler-McKay, P., Munteanu, M., … Traer, E. (2017). INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. In HAEMATOLOGICA (Vol. 102, pp. 217–218). Madrid, SPAIN: FERRATA STORTI FOUNDATION.
Cortes, J., D. DeAngelo, E. Wang, C. Arana-Yi, P. Zweidler-McKay, M. Munteanu, C. Andreu-Vieyra, H. Erba, W. Blum, and E. Traer. “INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML.” In HAEMATOLOGICA, 102:217–18. FERRATA STORTI FOUNDATION, 2017.
Cortes J, DeAngelo D, Wang E, Arana-Yi C, Zweidler-McKay P, Munteanu M, et al. INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 217–8.
Cortes, J., et al. “INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML.” HAEMATOLOGICA, vol. 102, FERRATA STORTI FOUNDATION, 2017, pp. 217–18.
Cortes J, DeAngelo D, Wang E, Arana-Yi C, Zweidler-McKay P, Munteanu M, Andreu-Vieyra C, Erba H, Blum W, Traer E. INITIAL RESULTS FROM A FIRST-IN-HUMAN STUDY OF IMGN779, A CD33-TARGETING ANTIBODY-DRUG CONJUGATE (ADC) WITH NOVEL DNA ALKYLATING ACTIVITY, IN PATIENTS WITH RELAPSED OR REFRACTORY AML. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2017. p. 217–218.
Published In
HAEMATOLOGICA
ISSN
0390-6078
Publication Date
June 26, 2017
Volume
102
Start / End Page
217 / 218
Location
Madrid, SPAIN
Publisher
FERRATA STORTI FOUNDATION
Conference Name
22nd Congress of the European-Hematology-Association
Related Subject Headings
- Immunology
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology